title: Ghrelin receptor (GHS-R1A) antagonism suppresses both alcohol consumption and the alcohol deprivation effect in rats following long-term voluntary alcohol consumption.
abstract: Alcohol dependence is a heterogeneous disorder where several signalling systems play important roles. Recent studies implicate that the gut-brain hormone ghrelin, an orexigenic peptide, is a potential mediator of alcohol related behaviours. Ghrelin increases whereas a ghrelin receptor (GHS-R1A) antagonist decreases alcohol consumption as well as operant self-administration of alcohol in rodents that have consumed alcohol for twelve weeks. In the present study we aimed at investigating the effect of acute and repeated treatment with the GHS-R1A antagonist JMV2959 on alcohol intake in a group of rats following voluntarily alcohol consumption for two, five and eight months. After approximately ten months of voluntary alcohol consumption the expression of the GHS-R1A gene (Ghsr) as well as the degree of methylation of a CpG island found in Ghsr was examined in reward related brain areas. In a separate group of rats, we examined the effect of the JMV2959 on alcohol relapse using the alcohol deprivation paradigm. Acute JMV2959 treatment was found to decrease alcohol intake and the effect was more pronounced after five, compared to two months of alcohol exposure. In addition, repeated JMV2959 treatment decreased alcohol intake without inducing tolerance or rebound increase in alcohol intake after the treatment. The GHS-R1A antagonist prevented the alcohol deprivation effect in rats. There was a significant down-regulation of the Ghsr expression in the ventral tegmental area (VTA) in high- compared to low-alcohol consuming rats after approximately ten months of voluntary alcohol consumption. Further analysis revealed a negative correlation between Ghsr expression in the VTA and alcohol intake. No differences in methylation degree were found between high- compared to low-alcohol consuming rats. These findings support previous studies showing that the ghrelin signalling system may constitute a potential target for development of novel treatment strategies for alcohol dependence.
authors: Institute of Neuroscience and Physiology, Department of Pharmacology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
authors: Petra
authors: P
authors: Suchankova
authors: Pia
authors: P
authors: Steensland
authors: Ida
authors: I
authors: Fredriksson
authors: Jörgen A
authors: JA
authors: Engel
authors: Elisabet
authors: E
authors: Jerlhag
mesh_terms: D000284:Administration, Oral; D000428:Alcohol Drinking / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D000437:Alcoholism / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D000818:Animals; D018899:CpG Islands; D019175:DNA Methylation / Q000187:drug effects; D005786:Gene Expression Regulation; D054439:Ghrelin / Q000235:genetics / Q000378:metabolism*; D005998:Glycine / Q000031:analogs & derivatives* / Q000494:pharmacology; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D054440:Receptors, Ghrelin / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D012646:Self Administration; D015398:Signal Transduction; D013375:Substance Withdrawal Syndrome / Q000517:prevention & control*; D014230:Triazoles / Q000494:pharmacology*; D017557:Ventral Tegmental Area / Q000187:drug effects*
chemical_list: D054439:Ghrelin; C569751:N-(1-(4-(4-methoxybenzyl)-5-phenethyl-4H-1,2,4-triazol-3-yl)-2-(1H-indol-3-yl)ethyl)-2-aminoacetamide; D054440:Receptors, Ghrelin; D014230:Triazoles; D005998:Glycine
references: Pharmacopsychiatry. 2009 May;42 Suppl 1:S87-94
references: 19434560
references: Addict Biol. 2008 Sep;13(3-4):358-63
references: 18782383
references: Alcohol. 2004 Jun;33(2):91-7
references: 15528006
references: Prog Neuropsychopharmacol Biol Psychiatry. 2004 Dec;28(8):1221-47
references: 15588749
references: Alcohol Alcohol. 2006 Sep-Oct;41(5):486-93
references: 16799162
references: Regul Pept. 2011 Dec 10;172(1-3):77-80
references: 21903141
references: Behav Brain Res. 2011 Aug 1;221(1):182-8
references: 21392542
references: Brain Res Mol Brain Res. 1997 Aug;48(1):23-9
references: 9379845
references: Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12518-23
references: 17626178
references: Mol Endocrinol. 2006 Aug;20(8):1772-85
references: 16601073
references: J Clin Endocrinol Metab. 2001 Dec;86(12):5992
references: 11739476
references: Neuroscience. 2011 Apr 28;180:129-37
references: 21335062
references: J Med Chem. 2007 Nov 15;50(23):5790-806
references: 17927165
references: Eur Neuropsychopharmacol. 2008 Jul;18(7):508-18
references: 18343642
references: Addict Biol. 2012 Jan;17(1):95-107
references: 21309956
references: Addict Biol. 2006 Mar;11(1):45-54
references: 16759336
references: Biol Psychiatry. 2009 Jul 15;66(2):185-90
references: 19249750
references: Alcohol. 2009 Feb;43(1):35-43
references: 19185208
references: Regul Pept. 2005 Feb 15;125(1-3):151-4
references: 15582726
references: J Neuroendocrinol. 2009 Sep;21(9):777-85
references: 19703102
references: Psychopharmacology (Berl). 2007 Dec;195(3):333-43
references: 17703283
references: Addict Biol. 2007 Mar;12(1):6-16
references: 17407492
references: Pharmacol Biochem Behav. 2007 Nov;88(1):89-93
references: 17764729
references: Psychopharmacologia. 1973;29(3):203-10
references: 4702273
references: JAMA. 2006 May 3;295(17):2003-17
references: 16670409
references: Alcohol Clin Exp Res. 2010 Sep 1;34(9):1525-34
references: 20586761
references: Neuron. 2012 Jan 26;73(2):317-32
references: 22284186
references: Regul Pept. 2007 May 3;140(3):148-52
references: 17257691
references: PLoS One. 2011 Mar 23;6(3):e18170
references: 21448464
references: Psychoneuroendocrinology. 2012 Jul;37(7):980-6
references: 22172639
references: Trends Pharmacol Sci. 1997 Feb;18(2):54-9
references: 9090311
references: Alcohol Clin Exp Res. 2008 Oct;32(10):1816-23
references: 18671810
references: Addict Biol. 2010 Jul;15(3):304-11
references: 20477752
references: Eur J Pharmacol. 1997 Sep 10;334(2-3):149-56
references: 9369343
references: Drug Alcohol Depend. 2011 Sep 1;117(2-3):126-31
references: 21310553
references: Alcohol Clin Exp Res. 2004 Nov;28(11):1683-92
references: 15547455
references: Alcohol Clin Exp Res. 2008 Dec;32(12):2054-61
references: 18828808
references: J Cell Physiol. 2009 May;219(2):243-50
references: 19127539
references: Alcohol Res Health. 2000;24(2):124-31
references: 11199279
references: Nat Rev Neurosci. 2007 May;8(5):355-67
references: 17453016
references: Psychoneuroendocrinology. 2013 Aug;38(8):1259-70
references: 23219472
references: J Clin Invest. 2006 Dec;116(12):3229-39
references: 17060947
references: Neurochem Int. 2009 Feb;54(2):89-94
references: 19118592
references: J Comp Neurol. 2006 Jan 20;494(3):528-48
references: 16320257
references: Alcohol. 2004 Oct-Nov;34(2-3):239-50
references: 15902919
references: Nat Rev Neurosci. 2004 Dec;5(12):963-70
references: 15550951
references: Alcohol Clin Exp Res. 2010 Sep 1;34(9):1519-24
references: 20586762
references: Addict Biol. 2012 Mar;17(2):452-64
references: 21392177
references: Psychopharmacology (Berl). 2012 Oct;223(3):299-306
references: 22547331
references: Neurosci Biobehav Rev. 2004 Jan;27(8):713-20
references: 15019421
references: Alcohol Clin Exp Res. 2004 Dec;28(12):1822-8
references: 15608598
references: Curr Drug Abuse Rev. 2008 Nov;1(3):280-91
references: 19630726
references: Alcohol Clin Exp Res. 2006 Nov;30(11):1933-7
references: 17067359
references: Psychopharmacology (Berl). 2009 Mar;203(1):99-108
references: 18987848
references: Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11318-23
references: 19564604
references: J Addict Med. 2013 Jul-Aug;7(4):277-86
references: 23728065
references: Neuropsychopharmacology. 2001 Feb;24(2):97-129
references: 11120394
references: Addict Biol. 2007 Mar;12(1):22-9
references: 17407494
references: Endocrinology. 2001 Oct;142(10):4163-9
references: 11564668
references: Alcohol. 2011 Jun;45(4):341-7
references: 21145690
references: Methods. 2001 Dec;25(4):402-8
references: 11846609
references: Addict Biol. 2011 Jan;16(1):82-91
references: 20579004
references: Mol Endocrinol. 2003 Nov;17(11):2201-10
references: 12907757
references: Eur J Pharmacol. 2003 Apr 25;467(1-3):85-93
references: 12706460
references: Addict Biol. 2012 Jan;17(1):86-94
references: 21309944
references: Nature. 2000 Oct 19;407(6806):908-13
references: 11057670
references: PLoS One. 2012;7(12):e50409
references: 23227170
references: Diabetes. 2001 Nov;50(11):2540-7
references: 11679432
references: Neuropsychopharmacology. 2003 Aug;28(8):1463-71
references: 12700689
references: Nature. 2001 Jan 11;409(6817):194-8
references: 11196643
references: Psychopharmacology (Berl). 2010 Sep;211(4):415-22
references: 20559820